Exciting news! Dynaheart Medical has been named on the 2023Venture50 list.

On 2024 1, 16, the results of the 2023Venture50 awards, initiated by Qingchuang Venture Capital (1945.HK) and Investment World, were finally announced! Dynaheart Medical was honored to be listed as an innovative enterprise in the heart failure field.

Venture50 Awards (V50), launched by Zero2IPO Group (1945.HK) in 2006, has evolved over 18 years into China's leading indicator of investment value for high-growth enterprises. In 2023, V50 reviewed thousands of startup projects, invited hundreds of venture capital firms, and engaged over a thousand investors to evaluate and select companies with disruptive and cutting-edge technologies!

Currently, Dynaheart Medical has established a comprehensive solution for heart failure and cardiovascular disease, covering high-risk PCI, cardiogenic shock from various causes, multi-organ failure, percutaneous mechanical support for cardiorenal syndrome, and a complete pipeline of surgical support products.

In the future, Dynaheart Medical will focus on developing new materials and intelligent control technologies, continuously iterating and innovating to meet the diverse needs of patients and healthcare providers. As a leader in the heart failure sector, we look forward to our innovative products providing valuable insights for advancing China's medical innovation industry.

Innovation leads the future. Dynaheart Medical remains committed to advancing the R&D and commercialization of heart failure medical devices, accelerating Chinese innovation for global benefit.